Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

962
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
962
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.4K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

593
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
593
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.4K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

728
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
728
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.1K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial.

United European gastroenterology journal·2026
Same author

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial.

Gut·2026
Same author

Waiting for cholecystectomy: determinants of prioritization for delayed cholecystectomy in a universal public healthcare system-post hoc analysis of RELAPSTONE cohort (WAIT-CHOL study).

BJS open·2026
Same author

Validation of Predictive Equations for Estimating Lean Soft Tissue and Fat-Free Mass in Class II-V Obesity: A Multicenter Observational Study with Implications for Bariatric Surgery Monitoring.

Journal of obesity & metabolic syndrome·2026
Same author

Editorial: Advancing gastrointestinal disease diagnosis with interpretable AI and edge computing for enhanced patient care.

Frontiers in medicine·2026
Same author

Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From the European Registry on Helicobacter pylori Management.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

相关实验视频

Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K

胃潰瘍疾病

Angel Lanas1, Francis K L Chan2

  • 1Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain.

Lancet (London, England)
|March 1, 2017
PubMed
概括

由于抗菌药物耐药性和复杂的治疗方法,胃病不太常见,但更难治疗. 不与H. pylori或NSAID相关的会带来新的挑战,需要更新治疗策略.

科学领域:

  • 胃肠病学
  • 内部医学
  • 药理学

背景情况:

  • 由于Helicobacter pylori感染率降低和质子抑制剂的使用增加,胃潰瘍疾病 (PUD) 的患病率有所降低.
  • 然而,PUD的治疗越来越复杂,原因是抗菌素耐药性增加和抗血栓治疗在老年人群中的广泛使用.
  • 越来越多与H.pylori或NSAID无关的病存在独特的诊断和治疗挑战.

研究的目的:

  • 提供当前知识和胃潰瘍疾病的最新进展的全面概述.
  • 讨论最新的H. pylori感染管理和PUD并发症治疗指南.
  • 突出复杂胃病例的诊断和治疗的未满足需求.

主要方法:

  • 关于胃潰瘍病原和流行病学的最新文献.
  • 对H. pylori根除和PUD管理的当前临床指南的分析.
  • 与抗血栓剂和NSAID相关的PUD治疗策略的讨论.
  • 识别知识缺口和未来的研究方向.

主要成果:

  • 与H. pylori相关的PUD的流行率正在下降.
  • 由于抗菌素耐药性和抗血栓药物使用,PUD管理面临越来越多的挑战.

更多相关视频

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

873
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K

相关实验视频

Last Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

873
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K
  • 非H. pylori,非NSAID的出现是一个重要的临床问题.
  • 需要更新治疗方法和进一步研究.
  • 结论:

    • 胃病的管理需要适应不断变化的流行病学趋势和治疗挑战.
    • 在接受抗血栓治疗的患者中,解决抗菌素耐药性和优化治疗至关重要.
    • 需要进一步的研究来了解和有效地治疗复杂的胃.